Daiwa Securities Group Inc. Has $2.88 Million Stock Position in Insulet Co. (NASDAQ:PODD)

Daiwa Securities Group Inc. grew its stake in Insulet Co. (NASDAQ:PODD) by 8.5% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 12,378 shares of the medical instruments supplier’s stock after buying an additional 973 shares during the quarter. Daiwa Securities Group Inc.’s holdings in Insulet were worth $2,881,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Tidal Investments LLC boosted its stake in Insulet by 58.8% in the 1st quarter. Tidal Investments LLC now owns 4,064 shares of the medical instruments supplier’s stock worth $697,000 after purchasing an additional 1,504 shares during the period. iA Global Asset Management Inc. bought a new position in shares of Insulet during the first quarter worth about $105,000. Swedbank AB acquired a new stake in Insulet in the 1st quarter valued at approximately $6,903,000. Beck Bode LLC lifted its stake in Insulet by 41.3% in the 1st quarter. Beck Bode LLC now owns 69,761 shares of the medical instruments supplier’s stock valued at $11,957,000 after acquiring an additional 20,373 shares in the last quarter. Finally, Teachers Retirement System of The State of Kentucky boosted its position in Insulet by 23.9% during the 1st quarter. Teachers Retirement System of The State of Kentucky now owns 35,035 shares of the medical instruments supplier’s stock worth $6,006,000 after acquiring an additional 6,754 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on PODD. Barclays lifted their price objective on shares of Insulet from $220.00 to $234.00 and gave the company an “equal weight” rating in a report on Monday, November 11th. Citigroup boosted their price target on shares of Insulet from $250.00 to $275.00 and gave the stock a “buy” rating in a research report on Tuesday, October 1st. Piper Sandler raised their price objective on Insulet from $230.00 to $285.00 and gave the company an “overweight” rating in a report on Tuesday, September 17th. BTIG Research upped their target price on Insulet from $260.00 to $270.00 and gave the stock a “buy” rating in a report on Friday, November 8th. Finally, Morgan Stanley raised their price target on Insulet from $234.00 to $317.00 and gave the company an “overweight” rating in a research note on Monday, November 11th. Three equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $253.27.

Insulet Price Performance

Shares of PODD opened at $266.92 on Thursday. The company’s 50-day moving average is $242.59 and its 200-day moving average is $212.36. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. The firm has a market capitalization of $18.72 billion, a PE ratio of 45.71, a PEG ratio of 4.08 and a beta of 1.22. Insulet Co. has a fifty-two week low of $160.19 and a fifty-two week high of $279.40.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.